Tagrisso (osimertinib)

pCPA File Number: 21713
Negotiation Status:
Active Negotiation
Indication(s):
Indicated as adjuvant therapy after tumour resection in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations
Sponsor/Manufacturer:
AstraZeneca Canada Inc.
CADTH Project Number:
PC0246
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable